S. Alice Long

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Kevan C. Herold, Brian N. Bundy, S. Alice Long et al. · New England Journal of Medicine · 2019 · 1K citations · Full text

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Jeffrey A. Bluestone, Jane H. Buckner, Mark Fitch et al. · Science Translational Medicine · 2015 · 993 citations

Translational Medicine, Diabetes Management, Autoimmune Disease +13

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes

Manuela Battaglia, Simi Ahmed, Mark S. Anderson et al. · Diabetes Care · 2019 · 331 citations · Full text

Metabolic Syndrome, Disease Heterogeneity, Translational Medicine +15

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

Emily K. Sims, Brian N. Bundy, Kenneth Stier et al. · Science Translational Medicine · 2021 · 331 citations · Full text

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

S. Alice Long, Mary Rieck, Srinath Sanda et al. · Diabetes · 2012 · 306 citations · Full text